Veranova celebrates the 20th anniversary of Pharmorphix®

This month, we are celebrating the 20th anniversary of Veranova’s solid form and particle engineering brand, Pharmorphix. In honour of this milestone, we are reflecting on the brand’s achievements over this period and looking forward to the bright and innovative future ahead.

Over the past two decades, Pharmorphix solid form offerings have enabled the creation of new, advanced pharmaceuticals, delivering vital therapeutics to patients in need. Founded in 2003 as a spin-out from Millennium Pharmaceuticals, and previously owned by Sigma Aldrich (2006) then Johnson Matthey (2015), Pharmorphix is now the solid form and particle engineering brand of Veranova.

From our state-of-the-art facility in Cambridge, UK, our team has provided world-leading, integrated solid form, pre-formulation, and particle engineering capabilities to the pharmaceutical and biotechnology industries. Pharmorphix continues to be a trusted pharmaceutical partner. Combining close collaboration with decades of extensive expertise, we can help you find life-changing solutions to even the most formidable drug development challenges.

Since its formation in 2003, Pharmorphix has successfully completed over 2,000 customer projects on a wide range of structurally diverse and complex APIs, and, over the last decade, our technology has benefited nearly 1 in 5 FDA approved small molecule drugs.

Craig Grant, Global Director of Solid Form & Particle Engineering, said, “As a part of Veranova, Pharmorphix’s presence in Cambridge has grown significantly over the years, from small beginnings of around eight people to over 50 employees today. Looking ahead, we are excited to continue applying our cutting-edge understanding of solid form science to accelerate route to market, improving the properties and success rates of drug candidates throughout the pharmaceutical industry.”

The Pharmorphix team would like to thank our clients, past and present, for their collaboration and trust. We are excited to continue our growth and development as a leading drug development partner and help deliver transformative medicines to patients across the world.